Drug intelligence / Profile preview

VN-100

Development stage: Preclinical
Lead developer: VentriNova
Modality: Gene Therapies

Overview

VN-100 is a preclinical-stage gene therapy developed by VentriNova. It is designed to regenerate heart muscle following a heart attack by delivering the cyclin A2 gene. The technology originated from research conducted at the Icahn School of Medicine at Mount Sinai.

Targets

CCNA2 (Cyclin A2)

Beyond the preview

Go deeper on VN-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VN-100.

Explore the full profile